Skip to content

Study · Animal study (in vivo) · mouse · 2008

6 results

Prokinetic effects of a ghrelin receptor agonist GHRP-6 in diabetic mice.

Zheng Q, Qiu WC, Yan J, Wang WG, Yu S, Wang ZG, Ai KX

World journal of gastroenterology1 Aug 2008Cited by 10 (Europe PMC)

PMID18720542 (opens in a new tab)PMCIDPMC2739343 (opens in a new tab)DOI10.3748/wjg.14.4795 (opens in a new tab)PepBankPUB-18720542
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, GHRP‑6 improved gastric emptying.

    In plain wordsIn diabetic mice, GHRP‑6 improved stomach emptying.

    Peptide
    GHRP-6
    Outcome
    IncreaseGastric emptying
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    20, 50, 100 and 200 microg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In the diabetic mice, GHRP-6 improved both GE and IT, but not CT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, GHRP‑6 improved intestinal transit.

    In plain wordsIn diabetic mice, GHRP‑6 improved movement through the intestine.

    Peptide
    GHRP-6
    Outcome
    IncreaseIntestinal transit
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    20, 50, 100 and 200 microg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In the diabetic mice, GHRP-6 improved both GE and IT, but not CT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, GHRP‑6 did not improve colonic transit.

    In plain wordsIn diabetic mice, GHRP‑6 did not improve movement through the colon.

    Peptide
    GHRP-6
    Outcome
    No significant changeColonic transit
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    20, 50, 100 and 200 microg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In the diabetic mice, GHRP-6 improved both GE and IT, but not CT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.
  4. 04AnimalAnimal study (in vivo)Activity measurement

    In diabetic mice, the most effective GHRP‑6 dose for prokinetic effects was 200 microg/kg.

    In plain wordsIn diabetic mice, 200 microg/kg was the most effective GHRP‑6 dose for gut movement.

    Peptide
    GHRP-6
    Outcome
    Not applicableMost effective prokinetic dose
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    200 microg/kg · intraperitonealAs given in this study (mouse).

    Measurements

    Most effective dose
    200 microg/kg
    GHRP-6 prokinetic effects

    Source sentences

    Summary
    The most effective dose of GHRP-6 was 200 microg/kg and atropine blocked the prokinetic effects of GHRP-6 on GE and IT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In diabetic mice, atropine blocked the effect of GHRP‑6 on gastric emptying.

    In plain wordsIn diabetic mice, atropine blocked the effect of GHRP‑6 on stomach emptying.

    Peptide
    GHRP-6
    Outcome
    DecreaseAtropine blockade of gastric emptying effect
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Source sentences

    Summary
    The most effective dose of GHRP-6 was 200 microg/kg and atropine blocked the prokinetic effects of GHRP-6 on GE and IT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In diabetic mice, atropine blocked the effect of GHRP‑6 on intestinal transit.

    In plain wordsIn diabetic mice, atropine blocked the effect of GHRP‑6 on intestinal movement.

    Peptide
    GHRP-6
    Outcome
    DecreaseAtropine blockade of intestinal transit effect
    Study

    mousen: not reported in source

    Alloxan-induced diabetes
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Source sentences

    Summary
    The most effective dose of GHRP-6 was 200 microg/kg and atropine blocked the prokinetic effects of GHRP-6 on GE and IT.
    2 context sentences
    Summary · context
    A diabetic mouse model was established by intraperitoneal injection with alloxan.
    Summary · context
    Mice were randomized into two main groups: normal mice and diabetic mice treated with GHRP-6 at doses of 0, 20, 50, 100 and 200 microg/kg ip.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.